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Gemcitabine and treosulfan are DNA-damaging agents. Preclinical studies suggest that synergism exists when melanoma cells are
exposed to both drugs concurrently. We conducted a phase I trial in advanced melanoma patients to determine the optimal dose of
gemcitabine to be combined with treosulfan. Cohorts of three patients received increasing doses of gemcitabine, commencing at
0.5gm
 2, followed by a fixed dose of 5.0gm
 2 treosulfan on day one of a 21-day cycle. Patients alternately received a first cycle of
single-agent gemcitabine or treosulfan before subsequent cycles of both drugs. Peripheral blood lymphocytes were collected in cycles
1 and 2 at various time points until 48h post-treatment. The single-cell gel electrophoresis (Comet) assay was used to measure
chemotherapy-induced DNA damage. A total of 27 patients were enrolled, no objective responses were observed, but two uveal
melanoma patients had minor responses. Dose-limiting myelosuppression was reached at 3.0gm
 2 gemcitabine. DNA single-strand
breaks were detected 4h post-gemcitabine, repaired by 24h. DNA interstrand crosslinks were detected 4h post-treosulfan, fully
removed by 48h. Following combination chemotherapy, treosulfan-induced DNA crosslinks persisted, still being detectable 48h
post-treatment, supporting the hypothesis that gemcitabine potentiates treosulfan-induced cytotoxicity. The recommended regimen
for further study is 2.5gm
 2 gemcitabine combined with 5.0gm
 2 treosulfan.
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Metastatic melanoma is a devastating disease. Melanomas most
commonly arise from the skin, more rarely from the uveal tract in
the eye. The incidence of melanoma varies worldwide. In western
countries, it stands at around 10–50 per 100000 per annum, and
its incidence is increasing faster than any other type of cancer.
Uveal melanoma, although the most common primary malignancy
involving the eye, is extremely rare, with annual incidence being
around seven per million of the population. On biological and
molecular grounds (Prescher et al, 1994; Woll et al, 1999; Davies
et al, 2002; Kefford et al, 2004), uveal melanoma is a separate
disease distinct from cutaneous melanoma. However, if local
control fails, prognosis for both groups of patients is extremely
poor, with median survival time being around 6 months (Woll et al,
1999; Chang et al, 1998; Balch et al, 2001). Melanoma is highly
resistant to chemotherapy and immunotherapy and no systemic
therapy has yet been shown to impact on survival of either patient
group (Bedikian et al, 1995; Nathan et al, 1997; Tsao et al, 2004).
Recently, the novel chemotherapy combination regimen, gemci-
tabine plus treosulfan (gemtreo), has shown preclinical (Cree et al,
1999; Neale et al, 1999) and clinical (Mayer et al, 1999; Szelenyi
et al, 1999; Pfohler et al, 2003) evidence of activity in both
cutaneous and uveal melanoma. Studies suggest that synergism
may exist between the alkylating agent, treosulfan and the
nucleoside analogue, gemcitabine, currently used to treat several
chemoresistant cancers. Gemcitabine is incorporated into DNA
which leads to masked chain termination, the major direct
cytotoxic action. It also inhibits ribonucleotide reductase, the
enzyme that produces deoxynucleotides required for DNA
synthesis and repair. As such, it is an agent which lends itself to
combination strategies, with potential to modulate cytotoxicity of
other drugs such as alkylating agents.
Treosulfan is a prodrug and is converted nonenzymatically to
L-diepoxybutane under physiological conditions (Feit et al, 1970).
Following conversion, alkylation of DNA and subsequent forma-
tion of DNA interstrand crosslinks is considered to be the
mechanism by which treosulfan elicits its cytotoxicity (Hartley
et al, 1999a,b).
The optimal administration schedule of gemcitabine and
treosulfan is not known, but clinical and pharmacological evidence
suggest that the two drugs are best administered on a single day.
A phase I study was undertaken to determine (1) the maximum
tolerated dose of gemcitabine combined with a fixed dose of
treosulfan, administered on day 1 of a 21-day cycle, (2) safety,
toxicity and efficacy of the combination chemotherapy regimen
and (3) whether gemcitabine affects the persistence of treosulfan-
induced DNA interstrand crosslinks.
PATIENTS AND METHODS
Patients
Patients with histological or cytological diagnosis of unresectable,
metastatic cutaneous or uveal malignant melanoma and aged 18
years or more were eligible for this study. Patients were required to
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shave bidimensionally measurable lesions, by either clinical or
radiological methods; predicted life expectancy of 12 weeks
or more and Eastern Cooperative Oncology Group (ECOG)
performance status p2. One line of prior chemotherapy was
allowed, in which case at least 6 weeks must have elapsed since
administration of previous treatment. Pretreatment laboratory
requirements were as follows: haemoglobin X10gdl
 1, platelets
X100 10
9l
 1, ANC X1.5 10
9l
 1, total bilirubin o1.3  upper
limit of normal (ULN), liver enzymes (ALT and ALP) o5 ULN,
Cr o1.5  ULN. Patients with any serious intercurrent medical
illnesses were excluded, as were pregnant or lactating women.
Women of child-bearing age were required to use effective
contraception. The trial received approval from the local research
ethics committee and all patients gave written informed consent to
take part.
Treatment of patients
Chemotherapy was administered on day 1 of a 21-day cycle.
Cohorts of three patients were treated with a fixed dose of 5gm
 2
treosulfan (Medac, UK), preceded by escalating doses of gemci-
tabine (Lilly Oncology, UK), commencing at a dose of 0.5g.m
2 and
increasing in increments of 0.5gm
 2. Treosulfan was administered
as a 1-h infusion and gemcitabine as a 30-min infusion.
Prophylactic intravenous and oral antiemetics were routinely
used. For the first treatment cycle only, patients were allocated
on an alternate basis to receive either gemcitabine or treosulfan
alone. For all subsequent cycles, the combination regimen was
given.
Physical examination, vital signs, toxicity evaluation (using the
National Cancer Institute Common Toxicity Criteria version 2)
and routine laboratory studies (FBC, biochemical profile, LDH)
were undertaken prior to each cycle of treatment. Measurable
disease was assessed every three cycles. Standard WHO criteria
were used to assess tumour response. Complete response (CR) was
defined as complete disappearance of all known disease deter-
mined by two observations not less than 4 weeks apart. Partial
response (PR) was defined as a decrease of 50% or more in the sum
of the products of the two maximum perpendicular diameters of
assessable disease for at least 4 weeks, with no appearance of new
lesions or progression of any lesion. Stable disease (SD) was
defined as a less than 50% decrease or a less than 25% increase in
the sum of the products of the two maximum perpendicular
diameters of assessable disease. Progressive disease (PD) was
defined as a 25% or more increase in the sum of the products of
the two maximum perpendicular diameters of assessable disease or
the development of any new lesions.
Dose-limiting toxicity (DLT) was predefined as any grade 3
or more toxicity (excluding alopecia, nausea and vomiting)
experienced during the first cycle of combination therapy
administered to any individual patient. When one patient
experienced DLT, a total of six patients were treated at this dose
level. The maximum tolerated dose (MTD) was defined if at least
two out of six patients experience DLT. A further six patients were
to be recruited at the dose level below the MTD to define the
maximum recommended dose (MRD) for further study. The MRD
was defined by a dose level that produced manageable and
reversible toxicity.
Drug-induced DNA damage
After cycles one and two, peripheral blood lymphocytes (PBLs)
were collected from all patients at 0h (pretreatment), 4, 24 and 48h
post-treatment. Peripheral blood lymphocytes were prepared on
each occasion from 8ml whole blood collected directly into a
Vacutainer
s CPTt tube. Each blood sample was centrifuged at
room temperature (1500g) for 20min. The white cell layer was
collected and cold RPMI 1640 medium containing 10% foetal calf
serum (FCS) and 2mML -glutamine was added. The sample was
centrifuged at 41C (200g), for 5min. The cells were resuspended in
2ml RPMI 1640 medium containing 10% FCS, 2mML -glutamine
and 10% dimethylsulphoxide and frozen as three aliquots at
 701C.
The single-cell gel electrophoresis (Comet) assay was used to
detect and quantitate chemotherapy-induced DNA damage in
patients’ PBLs. Details of the Comet assay are described elsewhere
(Spanswick et al, 1999). All procedures were carried out on ice and
in subdued lighting. All chemicals used were obtained from Sigma
Chemical Co. (Poole, UK) unless otherwise stated. Once thawed,
each PBL sample was diluted to give a final concentration of
2.5 10
4ml
 1. Each sample was then divided in two aliquots,
irradiated and unirradiated. Immediately before analysis, the
appropriate PBL samples were irradiated (10Gy) in order to
deliver a fixed number of random DNA strand breaks. After
embedding cells in 1% low gelling temperature agarose on a
precoated microscope slide, the cells were lysed for 1h in lysis
buffer (100mM disodium EDTA, 2.5 M NaCl, 10mM Tris-HCl pH
10.5) containing 1% Triton X-100 added immediately before
analysis, and then washed every 15min in distilled water for 1h.
Slides were then incubated in alkali buffer (50mM NaOH, 1mM
disodium EDTA, pH12.5) for 45min followed by electrophoresis in
the same buffer for 25min at 18V (0.6Vcm
 1), 250mA. The slides
were finally rinsed in neutralising buffer (0.5 M Tris-HCl, pH 7.5),
and then in saline.
After drying, the slides were stained with propidium iodide
(2.5mgml
 1) for 30min, then rinsed in distilled water. Images were
visualised using a NIKON inverted microscope with high-pressure
mercury light source, 510–560nm excitation filter and 590nm
barrier filter at  20 magnification. Images were captured using an
online CCD camera and analysed using Komet Analysis software
version 4.0 (Kinetic Imaging, Liverpool, UK). For each duplicate
slide, 25 cells were analysed. The tail moment for each image
was calculated using the Komet Analysis software as the product
of the percentage DNA in the comet tail and the distance between
the means of the head and tail distributions, based on the
definition of Olive et al (1990). In patients receiving single agent
treosulfan, crosslinking was expressed as percentage decrease in
tail moment compared to irradiated controls calculated by the
formula:
%decreaseintailmoment ¼½ 1  ð TMdi TMcu
TMci TMcuÞ  100
In patients receiving treosulfan and gemcitabine in combination,
crosslinking was expressed as percentage decrease in tail moment
compared to irradiated controls calculated by the formula below.
This formula was used to compensate for the additional single-
strand breaks induced by gemcitabine in addition to those
produced by the irradiation step.
%decreaseintailmoment ¼½ 1  ð TMdi TMcu
ðTMci TMcuÞþðTMdu TMcuÞÞ  100
whereTMdi¼tail moment of drug-treated irradiated sample;
Tmdu¼tail moment of drug-treated unirradiated sample;
TMcu¼tail moment of untreated, unirradiated control; TMci¼
tail moment of untreated, irradiated control.
RESULTS
From August 29 2000 until November 13 2002, 27 advanced
melanoma patients were enrolled, of whom 22 (81%) had
cutaneous and five (19%) had uveal primaries. The median age
was 50 (range 23–73) years. The majority of patients had
metastases involving the liver (Table 1). In all, 10 patients (nine
cutaneous, one uveal) had received prior chemotherapy with
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sdacarbazine. A total of 17 (63%) patients had ECOG performances
statue of zero at trial entry, the rest had an ECOG performance
status of 1.
Treatment administered and toxicity
All patients were assessable for toxicity (Table 2). The median
number of chemotherapy cycles received was 5 (range 1–15).
Dose-limiting toxicity was reached at 3.0gm
 2 gemcitabine, when
two of six patients experienced grade III myelosupression
comprising both neutropenia and anaemia. At the lower gemci-
tabine dose of 2.5gm
 2, only one episode of grade III neutropenia
occurred. There were no episodes of febrile neutropenia. Other
common toxicities considered to be probably or definitely related
to chemotherapy administration were nausea and vomiting,
fatigue, skin rash and constipation. At the start of the study,
prophylactic domperidone or metoclopramide was routinely
prescribed. However, at the higher gemcitabine doses of
2.5gm
 2 and above, use of a 5HT3 antagonist with or without
dexamethasone proved to be more effective in controlling
symptoms. A variety of musculoskelatal and abdominal pains
were reported by patients treated in this study. Three patients
treated between gemcitabine dose levels 1.5 and 3gm
 2 experi-
enced severe abdominal pain, which could not be attributed to any
obvious cause other than treatment. The known toxicities of
gemcitabine, pulmonary toxicity, influenza-like symptoms and
peripheral oedema, were closely monitored with dose –escalation;
however, there did not appear to be an excess of events at the
higher dose levels. The recommended dose for phase II evaluation
associated with good patient tolerance was 2.5gm
 2 gemcitabine,
combined with 5.0gm
 2 treosulfan.
Response to treatment
A total of 26 patients were evaluable for response. No objective
CRs or PRs were documented, using WHO criteria. Best responses
Table 1 Patient characteristics
Characteristic No. of patients %
Total no of patients 27
Sex
Male 14 52
Female 13 48
Age
Median 50
Range 23–73
ECOG performance status
01 7 6 3
11 0 3 7
Melanoma primary site
Cutaneous 22 81
Uveal 5 19
Sites of metastasis
M1a 3 11
M1b 7 26
M1c 17 63
Prior chemotherapy
Cutaneous 9 33
Uveal 1 4
Table 2 Toxicities identified as either possibly, probably or very likely to be related to gemtreo combination chemotherapy
Gemcitabine dose level (gm
 2)
0.5 1.0 1.5 2.0 2.5 3.0
No. of pts treated 3 3 3 3 8 7
Total no. of treatment cycles 22 37 24 13 42 39
Toxicity grade 1/2 3 1/2 3 1/2 3 1/2 3 1/2 3 1/2 3
Toxicity
Haematological toxicity
Neutropenia 0 0 0 0 0 0 0 2 1 2 2 2
Anaemia 0 0 0 0 0 0 0 0 8 0 2 4
Thrombocytopaenia 0 0 0 0 0 0 0 0 0 1 0 0
Nonhaematological toxicity
N / V 0 01 01 01 1 2 6 1 1 5 2
Anorexia 5 0 3 0 5 0 2 0 12 0 11 2
Diarrhoea 0 0 0 0 0 0 0 0 1 0 0 0
Constipation 0 0 0 0 0 0 0 0 9 1 5 0
Fatigue 5 0 3 0 15 0 3 0 26 2 13 2
Skin rash 0 0 0 0 0 0 0 0 6 0 15 0
Oedema 0 0 1 0 0 0 0 0 1 0 0 1
Respiratory 1 0 3 0 1 0 0 0 3 0 2 0
Neurological 0 0 1 0 0 0 3 1 7 0 2 0
M / S 0 01 03 06 0 1 7 06 0
Abdominal pain 1 0 0 0 3 1 2 0 3 1 3 1
Alopecia 0 0 0 0 0 0 0 0 3 0 7 1
C V S 0 01 00 00 00 00 0
Elevated LFTs 0 0 0 0 0 0 0 0 0 0 2 0
Other 1 0 3 0 0 0 1 1 6 0 9 0
N/V¼nausea and vomiting; CVS¼cardiovascular symptoms; M/S¼musculoskeletal symptoms; LFTs¼liver function tests; pts¼patients.
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swere as follows: two (8%) minor responses (both uveal melanoma),
13 (46%) SD (10 cutaneous, two uveal) and 12 (46%) PD (10
cutaneous, one uveal). Overall disease control was therefore 54%.
Median survival was 36 weeks (range 5–121), with one patient lost
to follow-up. Median overall time to progression was 14 weeks
(range 3–74). More detailed outcome data for the uveal melanoma
patients is given in Table 3. The two minor responses occurred
with doses of gemcitabine of 0.5 and 3.0gm
 2 in patients with
extensive liver metastases. Median survival and time to progres-
sion for the uveal melanoma patients were 53 weeks (range 20–
103) and 27 weeks (range 7–38), respectively.
Comet assays
Comet assays were performed on samples from eight patients
(Table 4) who received doses of gemcitabine ranging between 1.5
Table 3 Clinical outcomes for the uveal melanoma patients
Trial
Pt ID.
Gemcitabine
dose (gm
 2)
Sites of
metastasis
First /second-line
therapy
No. of
cycles
Best
response
TTP
(weeks)
Survival
(weeks)
03 0.5 Liver First 12 MR 38 53
04 1.0 Lungs First 3 Progression 7 20
10 2.0 Liver, skin, bone First 6 Stable 14 53
19 3.0 Liver First 9 Stable 30 88
21 3.0 Liver Second 9 MR 27 103
TTP¼time to progression; MR¼minor response.
Table 4 Details of patient samples on which Comet assays were successfully performed
Patient
number
Primary
tumour
Gemcitabine
dose (gm
 2)
Cycle 1 PBLs:
Treosulfan alone
Cycle 1 PBLs:
Gemcitabine alone
Cycle 2 PBLs:
Gem/Treo combination
1 Skin 1.5 — Yes No
2 Skin 2.5 — Yes Yes
3 Skin 2.5 — Yes Yes
4 Skin 2.5 — — Yes
5 Skin 3.0 Yes — No
6 Skin 3.0 Yes — No
7 Skin 3.0 No — Yes
8 Uveal 3.0 — Yes Yes
Figure 1 Typical comet images: (A) unirradiated PBLs taken prior to drug treatment, (B) irradiated PBLs taken prior to drug treatment, (C) unirradiated
PBLs taken after treosulfan treatment and (D) irradiated PBLs taken after treosulfan treatment.
Gemcitabine and treosulfan phase I trial
PG Corrie et al
2000
British Journal of Cancer (2005) 92(11), 1997–2003 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sand 3.0gm
 2. Paired sets of samples (taken after cycle 1
administration of single agent and after cycle 2 administration of
the combination regimen) were available for three patients, all of
whom received gemcitabine alone as the first treatment cycle at a
dose of either 2.5 or 3.0gm
 2.
Typical comet images are shown in Figure 1. In control predose,
unirradiated PBLs, no DNA damage was detected and the high
molecular weight supercoiled DNA remained intact as shown in
Figure 1A. Following irradiation of cells with 10Gy to introduce a
fixed level of random DNA single-strand breaks, the resulting
shorter fragments of DNA migrated from the bulk of the DNA
during electrophoresis to produce the typical comet images
(Figure 1B). The extent of DNA damage was quantitated by image
analysis to produce a tail moment, defined as the product of the
percentage DNA in the comet tail and the distance between the
means of the head and tail distributions, based on the definition of
Olive et al (1990). In patients receiving treosulfan, both single
agent and combination, the tail moment was used to calculate the
percentage decrease in tail moment using the formula previously
described. Therefore, the greater the percentage decrease the
greater the level of DNA interstrand crosslinking. Following
treosulfan treatment, no drug-induced single-strand breakage
was detected in unirradiated cells (Figure 1C) and these cells
showed similar profiles to the nondrug treated controls
(Figure 1A). When the PBLs exposed to treosulfan were irradiated
(Figure 1D), comet tails were visible but with decreased length and
intensity compared to irradiated controls. The comet heads were
larger and of greater intensity compared to the nondrug-treated
irradiated control cells (Figure 1B) due to the retention of DNA by
the treosulfan-induced interstrand crosslinks. The decrease in
comet tail moment compared to nondrug-treated irradiated
control was used to quantitate the level of DNA interstrand
crosslinking. In contrast, following treatment with gemcitabine,
single-strand breaks were observed.
Gemcitabine-induced DNA single-strand breaks were detected
in PBLs following gemcitabine adminstration in the four patients
treated (Patient numbers 1, 2, 3 and 8 in Table 4). They formed
rapidly within 4h post-treatment and were repaired by 24h (data
not shown). DNA interstrand crosslinks induced by treosulfan
alone were detectable at 4h in the two patients studied (Patient
numbers 5 and 6 in Table 4) and were fully repaired within 48 and
24h, respectively (Figure 2A). In three patients studied after
receiving gemcitabine and treosulfan in combination (Patient
numbers 2, 3 and 8 in Table 4), treosulfan-induced DNA
interstrand crosslinks were detected at 4h at equivalent levels to
those seen in patients receiving treosulfan alone. However,
increased levels of treosulfan-induced DNA interstrand crosslinks
were detectable at 24 and 48h (Figure 2B) and no repair was
observed. These findings support the original hypothesis that
gemcitabine may affect the persistance of treosulfan-induced DNA
interstrand crosslinks.
DISCUSSION
Gemcitabine combined with treosulfan is a novel combination
chemotherapy regimen with preliminary preclinical and clinical
evidence of activity in a variety of tumour types. The most
promising results appear to be in uveal melanoma. The first phase
I trial with this regimen combined gemcitabine and treosulfan on
days 1 and 8 of a 28-day cycle in patients with various advanced
solid tumours (Szelenyi et al, 1999). In this study, the dose of
gemcitabine was fixed at 1gm
 2. The dose of treosulfan was then
escalated from 2.5gm
 2 at 500mgm
 2 increments, and the
recommended dose of treosulfan to be used in this combination
schedule was 3.5gm
 2. The MTD was defined on conventional
toxicity criteria, with thrombocytopaenia and neutropaenia being
dose limiting. Of the original 20 patients enrolled in that study, two
PRs (one renal, one ovary) and five (three uveal melanoma, two
colorectal) minor responses were observed. This study was
extended to include 33 patients with metastatic uveal melanoma.
Although only one further partial response was observed, there
were trends in improved survival at the highest treosulfan dose
level (Schmittel et al, 2004).
A retrospective review of 14 patients with metastatic uveal
melanoma treated in seven centres across Europe with four
different schedules of gemcitabine (0.5–1gm
 2) combined with
treosulfan (3.5–5gm
 2) given either once on a 21-day schedule, or
on days 1 and 8 of a 28-day schedule, was recently reported
(Pfohler et al, 2003). The objective response rate was 29% (one CR
and three PRs), progression-free survival was 28 weeks, median
overall survival was 61 weeks and 1-year survival rate was 80%. All
of the schedules used were well tolerated, the most common side
effects being neutropaenia and thrombocytopaenia.
The optimal schedule of gemcitabine combined with treosulfan
has not yet been defined and the pharmacological basis for
synergism existing between these two agents has not previously
been ascertained. We hypothesised that the main cytotoxic event
with the combination gemtreo regimen would be the formation of
DNA interstrand crosslinks induced by treosulfan-derived pro-
ducts, which persist in the presence of gemcitabine. Since
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Figure 2 (A) Formation and repair of DNA interstrand crosslinks in
lymphocytes from patients receiving treosulfan alone (patients 5 and 6).
Results are expressed as percentage decrease in tail moment. (B)
Persistence of treosulfan-induced DNA interstrand crosslinks following
administration in combination with gemcitabine (patients 2, 3 and 8).
Results are expressed as percentage decrease in tail moment.
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streosulfan is conventionally administered at doses of 5–7gm
 2
once every 21 days, in this phase I trial, we fixed the dose of
treosulfan at 5gm
 2, escalated the dose of gemcitabine and
measured the amount of DNA damage induced by each drug alone
and by the combination regimen. Clinically, this combination
regimen administered on a 3 weekly basis was well tolerated, with
DLT being neutropaenia and anaemia at the gemcitabine dose level
of 3.0gm
 2. No thrombocytopaenia was recorded. Other sig-
nificant toxicities were fatigue and nausea, with sickness more
effectively controlled by using prophylactic 5HT3 antagonist
antiemetics. The recommended regimen for phase II evaluation
associated with good patient tolerability is 2.5gm
 2 gemcitabine,
combined with 5.0gm
 2 treosulfan, administered once every 3
weeks.
DNA damage induce by both drugs given alone or in
combination was detected and quantitated using the single-cell
gel electrophoresis (Comet) assay. The Comet assay allows
measurement of DNA damage at a single-cell level. It has been
modified to allow the sensitive detection and quantitation of DNA
interstrand crosslinking and can be applied to both preclinical and
clinical situations (Hartley et al, 1999a,b, 2004; Spanswick et al,
2002). Comet assay results could only be obtained from a limited
number of patients treated in this clinical study. Even so, single-
strand DNA breaks were consistently detected following gemcita-
bine alone at 4h and were fully repaired by 24h (data not shown).
Interstrand DNA crosslinks induced by treosulfan alone were
detectable at 4h and were fully repaired by 48h. Following
combination chemotherapy, treosulfan-induced DNA crosslinks
persisted, being detectable at high levels 48h post-treatment. These
Comet assay results support the general hypothesis that gemcita-
bine may affect the persistance of treosulfan-induced DNA
interstrand crosslinks.
The optimal dose of gemcitabine recommended from this study
to be used in the gemtreo combination regimen is potentially at
odds with current understanding of the intracellular metabolism of
gemcitabine, which is considered to be saturated at an optimal
fixed dose rate of 10mgm
 2min
 1 (Tempero et al, 2003). These
comet assay data were insufficient to determine the existence or
otherwise of a dose effect on DNA damage induced by increasing
gemcitabine doses used in this study.
In terms of clinical efficacy, although no objective responses
were seen, two of five uveal melanoma patients entered in this trial,
both with extensive liver metastases, experienced a minor response
and these occurred in patients treated at the lowest and highest
gemcitabine dose levels. The limited number of uveal melanoma
patients treated in this trial prohibits any firm conclusions
regarding the possibility of a gemcitabine dose response. However,
these findings would certainly support previously published
clinical data suggesting that the gemtreo regimen is an active
regimen in the treatment of metastatic uveal melanoma.
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